M. Ayhan Et Al. , "Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?," CURRENT PROBLEMS IN CANCER , vol.45, no.3, 2021
Ayhan, M. Et Al. 2021. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?. CURRENT PROBLEMS IN CANCER , vol.45, no.3 .
Ayhan, M., Turan, N., Kostek, O., Tufan, G., Ozyukseler, D. T., Odabas, H., ... Sakin, A.(2021). Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?. CURRENT PROBLEMS IN CANCER , vol.45, no.3.
Ayhan, Murat Et Al. "Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?," CURRENT PROBLEMS IN CANCER , vol.45, no.3, 2021
Ayhan, Murat Et Al. "Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?." CURRENT PROBLEMS IN CANCER , vol.45, no.3, 2021
Ayhan, M. Et Al. (2021) . "Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?." CURRENT PROBLEMS IN CANCER , vol.45, no.3.
@article{article, author={Murat Ayhan Et Al. }, title={Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?}, journal={CURRENT PROBLEMS IN CANCER}, year=2021}